MSH|^~\&|LAB|ARH|||201912051129||ORU^R01|4123928|D|2.3|||AL|NE
PID|1||AB00008388|AB8306|LABTEST^UCI^ROSE||19851010|F||||||||||AB000737/19|9874794993
OBR|1|36519^LAB|00027687^0512:C00003R^LAB^051219:C3^36519|500.1500^CP4^Chem 4 - Lytes^^^24326-1||201912051100|201912051102|||||||201912051102||||||||||LAB|F||||
OBX|1|ST|500.1900^NA^Sodium^^2951-2^2951-2|1|160^^Y|mmol/L|135-145|H||A^S|F|||201912051129
OBX|2|ST|500.2000^K^Potassium^^2823-3^2823-3|1|2.5^^Y|mmol/L|3.5-5.0|LL||A^S|F|||201912051129
NTE|1||*CRITICAL VALUE
OBX|3|ST|500.2100^CL^Chloride^^2075-0^2075-0|1|110^^Y|mmol/L|98-108|H||A^S|F|||201912051129
OBX|4|ST|500.2200^BICARB^Bicarbonate^^1962-0^1962-0|1|25^^Y|mmol/L|20-30|N||A^S|F|||201912051129
OBX|5|ST|500.2300^GAP^Anion Gap^^33037-3^33037-3|1|25^^Y|mmol/L|3-16|H||A^S|F|||201912051129
OBR|2|36519^LAB|00027687^0512:C00003R^LAB^051219:C3^36519|500.3900^MG^Magnesium^^2601-3^2601-3||201912051100|201912051102|||||||201912051102||||||||||LAB|F||||
OBX|1|ST|500.3900^MG^Magnesium^^2601-3^2601-3|1|1.0^^Y|mmol/L|0.7-1.2|N||A^S|F|||201912051129
NTE|1||In management of Eclampsia, the reference range is not
NTE|2||transferable as a therapeutic range.
OBR|3|36519^LAB|00027687^0512:C00003R^LAB^051219:C3^36519|520.4200^IRON^Iron Studies Profile^^^50190-8||201912051100|201912051102|||||||201912051102||||||||||LAB|F||||
OBX|1|ST|520.4300^FE^Iron^^14798-3^14798-3|1|30^^Y|umol/L|9-30|N||A^S|F|||201912051129
OBX|2|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|40^^Y|umol/L|45-70|L||A^S|F|||201912051129
OBX|3|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.75^^Y||0.15-0.55|H||A^S|F|||201912051129
NTE|1||Markedly elevated transferrin saturation.  Follow up and
NTE|2||management as per BCMA/MSP Iron Overload protocol.